CA2461890C - Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes - Google Patents
Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes Download PDFInfo
- Publication number
- CA2461890C CA2461890C CA2461890A CA2461890A CA2461890C CA 2461890 C CA2461890 C CA 2461890C CA 2461890 A CA2461890 A CA 2461890A CA 2461890 A CA2461890 A CA 2461890A CA 2461890 C CA2461890 C CA 2461890C
- Authority
- CA
- Canada
- Prior art keywords
- active compound
- nano
- polymer
- recited
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 59
- 230000002209 hydrophobic effect Effects 0.000 title description 6
- 239000011149 active material Substances 0.000 title description 2
- 229920000642 polymer Polymers 0.000 claims abstract description 188
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 239000002245 particle Substances 0.000 claims abstract description 53
- 239000006185 dispersion Substances 0.000 claims description 32
- 229920001282 polysaccharide Polymers 0.000 claims description 27
- 150000004676 glycans Chemical class 0.000 claims description 26
- 239000005017 polysaccharide Substances 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 238000005411 Van der Waals force Methods 0.000 claims description 5
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims description 3
- 229920002845 Poly(methacrylic acid) Chemical class 0.000 claims description 3
- 239000005062 Polybutadiene Chemical class 0.000 claims description 3
- 229920002873 Polyethylenimine Chemical class 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Chemical class 0.000 claims description 3
- 229920002125 Sokalan® Chemical class 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical class C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001197 polyacetylene Chemical class 0.000 claims description 3
- 239000004584 polyacrylic acid Chemical class 0.000 claims description 3
- 229920002857 polybutadiene Chemical class 0.000 claims description 3
- 229920001195 polyisoprene Chemical class 0.000 claims description 3
- 229920002451 polyvinyl alcohol Chemical class 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 150000004032 porphyrins Chemical class 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 42
- 150000002634 lipophilic molecules Chemical class 0.000 abstract description 25
- 239000000126 substance Substances 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 150000002433 hydrophilic molecules Chemical class 0.000 abstract description 10
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 235000013373 food additive Nutrition 0.000 abstract description 3
- 239000002778 food additive Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 72
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 67
- 229960002626 clarithromycin Drugs 0.000 description 66
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 58
- 239000003814 drug Substances 0.000 description 50
- 229940079593 drug Drugs 0.000 description 43
- 229960003276 erythromycin Drugs 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 239000002904 solvent Substances 0.000 description 29
- 230000008569 process Effects 0.000 description 25
- 230000003993 interaction Effects 0.000 description 16
- 239000002502 liposome Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- 229920000858 Cyclodextrin Polymers 0.000 description 11
- 239000003125 aqueous solvent Substances 0.000 description 11
- 239000011162 core material Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000412 dendrimer Substances 0.000 description 8
- 229920000736 dendritic polymer Polymers 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- -1 antigonadotropins Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940097362 cyclodextrins Drugs 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 229920002521 macromolecule Polymers 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000007908 nanoemulsion Substances 0.000 description 7
- 239000006070 nanosuspension Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 239000003120 macrolide antibiotic agent Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000005063 solubilization Methods 0.000 description 6
- 230000007928 solubilization Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002906 microbiologic effect Effects 0.000 description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 229920000856 Amylose Polymers 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002077 nanosphere Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002083 X-ray spectrum Methods 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000005660 hydrophilic surface Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000065675 Cyclops Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010661 oregano oil Substances 0.000 description 1
- 229940111617 oregano oil Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Colloid Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
L'invention concerne des particules nanométriques solubles formées d'un noyau (composé lipophile insoluble dans l'eau ou composé hydrophile) et d'un polymère amphiphile, lesdites particules présentant une meilleure solubilité et/ou stabilité. Ledit composé lipophile desdites particules nanométriques solubles peut se présenter sous la forme de composés pharmaceutiques, d'additifs alimentaires, d'agents cosmétiques, de produits agricoles et vétérinaires. L'invention concerne également de nouveaux procédés de fabrication desdites particules nanométriques solubles, ainsi qu'un nouveau réacteur chimique destiné à la fabrication d'un complexe d'inclusion contenant lesdites particules nanométriques solubles.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/966,847 | 2001-09-28 | ||
| US09/966,847 US6878693B2 (en) | 2001-09-28 | 2001-09-28 | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US10/256,023 US7081450B2 (en) | 2001-09-28 | 2002-09-26 | Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production |
| US10/256,023 | 2002-09-26 | ||
| PCT/IB2002/004176 WO2003028700A2 (fr) | 2001-09-28 | 2002-09-27 | Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes et dispositif et procede de fabrication de celles-ci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2461890A1 CA2461890A1 (fr) | 2003-04-10 |
| CA2461890C true CA2461890C (fr) | 2010-12-14 |
Family
ID=32474076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2461890A Expired - Fee Related CA2461890C (fr) | 2001-09-28 | 2002-09-27 | Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1448174A2 (fr) |
| JP (1) | JP2005507393A (fr) |
| CA (1) | CA2461890C (fr) |
| IL (1) | IL160957A0 (fr) |
| WO (1) | WO2003028700A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111856A3 (fr) | 2002-08-12 | 2014-09-10 | Bend Research, Inc. | Compositions pharmaceutiques de médicaments partiellement ordonnés et polymères |
| US20060039948A1 (en) * | 2002-11-14 | 2006-02-23 | Gunther Schmid | Implant, therapeutic agent and micelle |
| EP1670516A2 (fr) * | 2003-09-30 | 2006-06-21 | Solubest Ltd | Nanoparticules hydrosolubles et leur procede de production |
| CN101040848B (zh) * | 2007-04-19 | 2010-05-19 | 上海交通大学 | 两亲性聚合物载药纳米粒子的制备方法 |
| EP2601935A1 (fr) * | 2007-09-25 | 2013-06-12 | Solubest Ltd. | Compositions comprenant des composés actifs lipophiles et procédé pour leur préparation |
| AU2013256064B2 (en) * | 2012-05-03 | 2018-01-04 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR101610465B1 (ko) * | 2014-04-11 | 2016-04-07 | 국립암센터 | 다목적용 의료 영상 표지자 및 이의 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| JP3072340B2 (ja) * | 1991-10-21 | 2000-07-31 | ポーラ化成工業株式会社 | 水性目薬及びその製造法 |
| WO1997004756A2 (fr) * | 1995-07-26 | 1997-02-13 | Nanosystems L.L.C. | Tensioactifs a squelette de methacrylate dans des formulations nanoparticulaires |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| JP2003501379A (ja) * | 1999-06-02 | 2003-01-14 | ナノファーマ アーゲー | ガン治療のための薬剤を充填したナノパーティクルの使用 |
| JP3523821B2 (ja) * | 2000-02-09 | 2004-04-26 | ナノキャリア株式会社 | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
| EP1258241A1 (fr) * | 2001-05-16 | 2002-11-20 | BIOPROGRESS S.p.A. | Procédé permettant d'accroitre la biodisponibilité de nimesulide |
-
2002
- 2002-09-27 WO PCT/IB2002/004176 patent/WO2003028700A2/fr not_active Application Discontinuation
- 2002-09-27 JP JP2003532033A patent/JP2005507393A/ja active Pending
- 2002-09-27 CA CA2461890A patent/CA2461890C/fr not_active Expired - Fee Related
- 2002-09-27 EP EP02800217A patent/EP1448174A2/fr not_active Withdrawn
- 2002-09-27 IL IL16095702A patent/IL160957A0/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005507393A (ja) | 2005-03-17 |
| CA2461890A1 (fr) | 2003-04-10 |
| WO2003028700A2 (fr) | 2003-04-10 |
| WO2003028700A3 (fr) | 2004-06-17 |
| EP1448174A2 (fr) | 2004-08-25 |
| IL160957A0 (en) | 2004-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002362475B2 (en) | Water soluble nanoparticles of hydrophilic and hydrophobic active materials | |
| AU2002362475A1 (en) | Water soluble nanoparticles of hydrophilic and hydrophobic active materials | |
| Rivas et al. | Nanoprecipitation process: From encapsulation to drug delivery | |
| Sur et al. | Recent developments in functionalized polymer nanoparticles for efficient drug delivery system | |
| Wang et al. | Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin | |
| Thassu et al. | Nanoparticulate drug-delivery systems: an overview | |
| Li et al. | Amphiphilic chitosan derivative-based core–shell micelles: Synthesis, characterisation and properties for sustained release of Vitamin D3 | |
| CN100462066C (zh) | 药剂的新制剂及其制备和应用方法 | |
| Anwunobi et al. | Recent applications of natural polymers in nanodrug delivery | |
| US20050191359A1 (en) | Water soluble nanoparticles and method for their production | |
| JP2006514698A5 (fr) | ||
| Sadaquat et al. | Biodegradable and biocompatible polymeric nanoparticles for enhanced solubility and safe oral delivery of docetaxel: In vivo toxicity evaluation | |
| Rong et al. | Applications of polymeric nanocapsules in field of drug delivery systems | |
| Patel et al. | Safety and toxicity issues of polymeric nanoparticles: A serious concern | |
| Majuru et al. | Nanotechnology in drug development and life cycle management | |
| Ullah et al. | Formulation development and characterization of pH responsive polymeric nano-pharmaceuticals for targeted delivery of anti-cancer drug (methotrexate) | |
| CN102357077A (zh) | 一种包裹难溶性药物的蛋白纳米颗粒及其制备方法 | |
| CA2461890C (fr) | Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes | |
| Baviskar et al. | Development and evaluation of N-acetyl glucosamine-decorated vitamin-E-based micelles incorporating resveratrol for cancer therapy | |
| Maruthi et al. | Nanoparticles–a review | |
| Hnawate et al. | Nanoparticle-novel drug delivery system: A Review | |
| Gholami et al. | Formulation of double microemulsion based on pH-responsive PEG/PVA/zinc oxide as a potential nano-platform for drug delivery: Green synthesis, and physico-chemical characterization | |
| Choudhury et al. | A review on nanoparticle: Types, preparation and its characterization | |
| Gultekin et al. | PLGA-Based nanomaterials for cancer therapy | |
| KrishnaSailaja et al. | An overall review on polymeric nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130927 |